Rezo Therapeutics

Executive Summary

Rezo Therapeutics is a preclinical precision oncology company based in San Francisco, founded in 2021. The company leverages human genetics and functional genomics to systematically identify genetic dependencies in cancer, enabling the discovery of novel, high-value drug targets. By analyzing large-scale genetic and genomic data, Rezo's platform pinpoints vulnerabilities that are specific to cancer cells, aiming to develop targeted therapies with improved efficacy and reduced side effects. The company has raised $78 million to date and is building a pipeline of programs focused on oncology indications. Given its early stage, Rezo Therapeutics has not yet advanced any candidate into clinical trials. The company's progress depends on successfully validating its platform and advancing lead programs toward IND-enabling studies. The precision oncology space is competitive, but Rezo's approach of combining human genetics with functional genomics offers a differentiated strategy. The company's ability to secure additional funding, form partnerships, and generate compelling preclinical data will be critical to its near-term success. With a strong scientific foundation and a clear focus on genetically validated targets, Rezo is positioned to make meaningful contributions to cancer therapy.

Upcoming Catalysts (preview)

• Q4 2026Series B funding round60% success
• Q2 2027Lead program nomination and preclinical data release50% success
• Q1 2027Strategic partnership with a larger pharmaceutical company40% success